TW200619212A - Morpholine derivatives - Google Patents
Morpholine derivativesInfo
- Publication number
- TW200619212A TW200619212A TW094130939A TW94130939A TW200619212A TW 200619212 A TW200619212 A TW 200619212A TW 094130939 A TW094130939 A TW 094130939A TW 94130939 A TW94130939 A TW 94130939A TW 200619212 A TW200619212 A TW 200619212A
- Authority
- TW
- Taiwan
- Prior art keywords
- bond
- optionally substituted
- ring
- morpholine derivatives
- represents optionally
- Prior art date
Links
- 150000002780 morpholines Chemical class 0.000 title 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004261655 | 2004-09-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200619212A true TW200619212A (en) | 2006-06-16 |
| TWI367209B TWI367209B (enExample) | 2012-07-01 |
Family
ID=36036551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094130939A TW200619212A (en) | 2004-09-08 | 2005-09-08 | Morpholine derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7935700B2 (enExample) |
| EP (1) | EP1801108B9 (enExample) |
| JP (1) | JP4970946B2 (enExample) |
| KR (1) | KR101011848B1 (enExample) |
| CN (1) | CN101014580B (enExample) |
| CA (1) | CA2579207C (enExample) |
| DK (1) | DK1801108T3 (enExample) |
| ES (1) | ES2396419T3 (enExample) |
| IN (1) | IN2014CN03493A (enExample) |
| PL (1) | PL1801108T3 (enExample) |
| PT (1) | PT1801108E (enExample) |
| TW (1) | TW200619212A (enExample) |
| WO (1) | WO2006028284A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE398616T1 (de) * | 2005-02-04 | 2008-07-15 | Ctg Pharma S R L | Neue 4-aminochinolinderivate als antimalariamittel |
| RS52711B (sr) | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US8030303B2 (en) | 2006-07-11 | 2011-10-04 | Mitsubishi Tanabe Pharma Corporation | Salt of morpholine compound |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) * | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| JP5313881B2 (ja) | 2007-04-04 | 2013-10-09 | 興和株式会社 | テトラヒドロイソキノリン化合物 |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| US10130634B2 (en) | 2013-07-24 | 2018-11-20 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for ophthalmic disease |
| KR102617531B1 (ko) | 2013-11-08 | 2023-12-27 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나제 억제제의 합성 방법 |
| WO2020203822A1 (ja) * | 2019-03-29 | 2020-10-08 | 千寿製薬株式会社 | 血管新生を伴う網膜疾患の治療又は予防のための併用医薬 |
| US12472166B2 (en) | 2019-08-26 | 2025-11-18 | Stichting Vumc | Inhibition of mycobacterial type VII secretion |
| EP4076448A4 (en) | 2019-12-20 | 2024-03-27 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| US20230312697A1 (en) | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63264467A (ja) | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
| US4870074A (en) * | 1986-04-30 | 1989-09-26 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, for enhancing gastrointestinal motility |
| JPH03148276A (ja) * | 1989-11-01 | 1991-06-25 | Yoshitomi Pharmaceut Ind Ltd | 光学活性なピリドンカルボン酸化合物 |
| WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| EP0920306A2 (en) | 1996-07-12 | 1999-06-09 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AU3633997A (en) | 1996-07-29 | 1998-02-20 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| CA2329821A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
| EP1076557A1 (en) | 1998-04-27 | 2001-02-21 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000031033A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
| CA2319435A1 (en) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Triazolo derivatives and chemokine inhibitors containing the same as effective component |
| AU2942000A (en) * | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| KR20010108394A (ko) | 1999-03-26 | 2001-12-07 | 다비드 에 질레스 | 신규 화합물 |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
| CA2423305A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Compounds useful in the treatment of inflammatory diseases |
| CA2423251A1 (en) * | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002088111A1 (en) | 2001-04-27 | 2002-11-07 | Mitsubishi Pharma Corporation | Novel benzylpiperidine compound |
| GB0207445D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| GB0207439D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0208158D0 (en) | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0207443D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| GB0212355D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| CA2490148A1 (en) * | 2002-07-02 | 2004-01-15 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
-
2005
- 2005-09-08 IN IN3493CHN2014 patent/IN2014CN03493A/en unknown
- 2005-09-08 EP EP05783689.2A patent/EP1801108B9/en not_active Expired - Lifetime
- 2005-09-08 KR KR1020077007863A patent/KR101011848B1/ko not_active Expired - Fee Related
- 2005-09-08 DK DK05783689.2T patent/DK1801108T3/da active
- 2005-09-08 US US11/662,228 patent/US7935700B2/en not_active Expired - Fee Related
- 2005-09-08 PL PL05783689T patent/PL1801108T3/pl unknown
- 2005-09-08 PT PT57836892T patent/PT1801108E/pt unknown
- 2005-09-08 JP JP2006535186A patent/JP4970946B2/ja not_active Expired - Fee Related
- 2005-09-08 CN CN2005800301370A patent/CN101014580B/zh not_active Expired - Fee Related
- 2005-09-08 TW TW094130939A patent/TW200619212A/zh not_active IP Right Cessation
- 2005-09-08 CA CA2579207A patent/CA2579207C/en not_active Expired - Fee Related
- 2005-09-08 ES ES05783689T patent/ES2396419T3/es not_active Expired - Lifetime
- 2005-09-08 WO PCT/JP2005/017002 patent/WO2006028284A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR101011848B1 (ko) | 2011-02-01 |
| PT1801108E (pt) | 2012-12-03 |
| CN101014580A (zh) | 2007-08-08 |
| JP4970946B2 (ja) | 2012-07-11 |
| KR20070099528A (ko) | 2007-10-09 |
| DK1801108T3 (da) | 2013-02-18 |
| EP1801108B9 (en) | 2013-11-20 |
| US7935700B2 (en) | 2011-05-03 |
| WO2006028284A1 (ja) | 2006-03-16 |
| TWI367209B (enExample) | 2012-07-01 |
| CA2579207C (en) | 2011-10-18 |
| EP1801108A4 (en) | 2010-10-13 |
| EP1801108B1 (en) | 2012-11-14 |
| EP1801108A1 (en) | 2007-06-27 |
| JPWO2006028284A1 (ja) | 2008-05-08 |
| PL1801108T3 (pl) | 2013-04-30 |
| US20070265257A1 (en) | 2007-11-15 |
| ES2396419T3 (es) | 2013-02-21 |
| IN2014CN03493A (enExample) | 2015-07-03 |
| CA2579207A1 (en) | 2006-03-16 |
| CN101014580B (zh) | 2011-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200619212A (en) | Morpholine derivatives | |
| TW200833675A (en) | Nicotinamide derivatives | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| TW200616994A (en) | Novel thiophene derivatives | |
| WO2007095174A3 (en) | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions | |
| WO2008108386A1 (ja) | 医薬組成物 | |
| DK1533292T3 (da) | Dibenzylaminforbindelse og medicinsk anvendelse deraf | |
| UA101352C2 (uk) | Конденсоване похідне амінодигідротіазину | |
| MXPA05011411A (es) | 1,4-diazepinas sustituidas y usos de las mismas. | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| ATE437872T1 (de) | Proteinkinaseinhibitoren | |
| TW200642683A (en) | Heterocyclic compound | |
| WO2002055496A8 (en) | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | |
| WO2004026248A3 (en) | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators | |
| TW200745034A (en) | New compounds | |
| TW200640900A (en) | 1-(2h)-isoquinolone derivative | |
| WO2006113552A3 (en) | Cyanoarylamines | |
| MXPA05011198A (es) | Derivados de oxifenilo aromaticos y de sulfanilfenilo aromaticos. | |
| ATE429429T1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| TNSN07006A1 (en) | Novel heterocyclic compounds | |
| MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
| TW200510361A (en) | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives | |
| MXPA04005077A (es) | Derivados de benzotiazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |